Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chevron Corp (CVX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Chevron CorpTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Chevron Corp vs Zimmer Biomet Holdings Inc — how do they compare? Chevron Corp trades at $180.53 (market cap $361.99B), while Zimmer Biomet Holdings Inc trades at $91.75 (market cap $17.61B). The key difference: Chevron Corp is far larger — about 20.6× Zimmer Biomet Holdings Inc's market cap, and Chevron Corp pays the higher dividend (3.92%). Which is the better fit depends on your goals.

CVXZBH
Market Cap
$361.99B$17.61B
Volume
9,807,834
Sector
EnergyHealth
52-Week High
$211.14$107.71
52-Week Low
$146.72$79.58
Enterprise Value
$402.09B$24.66B
Dividend Yield
3.92%1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chevron Corp

CVX trades at $182.21, up 3.29% on the day, with bullish technical signals from moving averages and ADX indicators. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.41 surpassing the $1.00 estimate. The company maintains strong operating cash flow of $33.94 billion in 2025 and announced a $13.8 billion investment in Argentina's Vaca Muerta shale project, signaling growth commitment.

The outlook remains positive with a consensus price target of $207.56, implying 13.9% upside. High oil prices and strategic expansions support growth, but declining profit margins and geopolitical tensions pose risks. Analyst sentiment is strongly bullish with 62% buy ratings, though investors should monitor debt levels, which rose to 12.35% of assets in 2025.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.

ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Chevron Corp

Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.

Read more on CVX

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH